Olumiant

Active Ingredient(s): Baricitinib
FDA Approved: * May 31, 2018
Pharm Company: * ELI LILLY AND CO
Category: Arthritis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Olumiant Overview

Baricitinib (trade name Olumiant) is a drug for the treatment of rheumatoid arthritis (RA), being developed by Incyte and Eli Lilly.[1] It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.[2] The drug is approved in Europe.[3] Contents 1 Approvals and indications 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacokinetics 6 History 6.1 Clinical trials 6.2 Approval process 7 See also 8 References ...

Read more Olumiant Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Baricitinib

Recent Olumiant Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Olumiant: (1 result)

Sorted by National Drug Code

• 0002-4182 Olumiant 2 mg Oral Tablet, Film Coated by Eli Lilly and Company

Other drugs which contain Baricitinib or a similar ingredient: (1 result)